By: ABRS- Clinical Insights Team
Abstract
Clinical research organizations often treat quality-related spending as a cost center that competes with timelines and operational efficiency. In practice, the greater financial and strategic burden frequently emerges when quality is addressed too late. Delayed enrollment, repeated monitoring activity, protocol deviations, query backlogs, safety-reporting deficiencies, incomplete trial master files, corrective and preventive actions, and retraining can all consume resources that were not visible in the original study budget.
This article examines why proactive quality management should be understood as an operational investment rather than an administrative obligation. It reviews the regulatory evolution from retrospective compliance checking toward Quality by Design (QbD), risk-based quality management (RBQM), and continuous oversight. Current guidance from the International Council for Harmonisation (ICH), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) consistently emphasizes identifying critical-to-quality factors, controlling meaningful risks, maintaining reliable electronic data, and ensuring that delegated activities remain appropriately overseen.
Recent evidence also strengthens the business case. A 2026 analysis of 18 oncology trials associated RBQM implementation with phase-duration reductions of 8% to 19%, monitoring-cost reductions of up to 18% under a modeled 10% source data verification scenario, and positive returns across the clinical phases examined (Dirks et al., 2026). These findings should not be generalized beyond the study’s scope without caution, but they demonstrate that quality-focused operating models can create measurable economic value in addition to supporting participant protection and data reliability.
Drawing on regulatory guidance and peer-reviewed research published between 2022 and 2026, this article presents a practical framework for building quality into clinical research from the outset. It also describes how ABRS can support sponsors through experienced functional expertise, structured oversight, risk-focused execution, and timely escalation while preserving sponsor visibility and decision-making authority.
Introduction
The most expensive quality problems in clinical research rarely begin as dramatic failures. They often start as small design assumptions, unclear responsibilities, incomplete training, delayed data review, poorly defined escalation pathways, or recurring site-level signals that are not evaluated early enough. Individually, each issue may appear manageable. Collectively, they can affect participant safety, compromise data reliability, slow database cleaning, increase monitoring effort, and weaken inspection readiness.
Traditional quality models have often concentrated on confirming compliance after activities occur: checking documents, reconciling data, reviewing source records, and correcting deviations. These controls remain important, but they cannot substitute for a study design and operating model that prevent avoidable errors. Manasco and Bhatt (2022) observed that conventional source data verification has long been treated as the standard approach to trial oversight despite limited evidence that it is the most effective way to identify critical errors. Their analysis supports the need to evaluate oversight methods according to their ability to detect risks that truly matter.
Regulatory expectations now make this shift explicit. The FDA’s adoption of ICH E8(R1) emphasizes designing quality into clinical studies by identifying critical-to-quality factors and focusing resources on activities essential to participant protection and the reliability of results (U.S. Food and Drug Administration [FDA], 2022). ICH E6(R3) extends that principle into trial conduct by promoting proportionate, risk-based quality management and effective oversight throughout the trial lifecycle (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [ICH], 2025).
Quality therefore should not be viewed as a final review step or a separate QA function. It is an operating discipline that connects protocol design, feasibility, site selection, training, monitoring, data management, safety surveillance, vendor governance, and documentation. When those functions operate with shared priorities and transparent information, emerging risks can be identified while they are still manageable.
At ABRS, we believe that proactive quality is built through experienced people, clear governance, disciplined execution, and timely decision-making. This article explores the hidden operational cost of reactive compliance, the regulatory foundation for QbD and RBQM, the practical controls that make proactive quality work, and the role of an integrated functional partner in helping sponsors maintain control while strengthening execution.
The Hidden Operational Cost of Reactive Compliance
Non-compliance does not create a single, predictable expense. Its cost is distributed across study functions and often appears only after timelines, resources, and vendor budgets have already been approved. A recurring consent error may require participant re-consent, document reconciliation, root-cause analysis, retraining, monitoring follow-up, and ethics committee communication. Delayed adverse-event review can require retrospective medical assessment and expanded reconciliation. Weak document management can create intensive trial master file remediation near database lock or inspection.
These consequences create both direct and opportunity costs. Direct costs include additional monitoring visits, expanded source data review, data-cleaning cycles, consultant support, system rework, CAPA development, and retraining. Opportunity costs arise when teams postpone database lock, redirect experienced personnel away from other programs, delay regulatory submissions, or lose time that cannot be recovered within a development plan. The financial impact is therefore not limited to the cost of correcting an individual record; it includes the disruption created across interconnected functions.
Protocol deviations illustrate this multiplier effect. A deviation may affect participant protection, endpoint interpretability, eligibility, investigational product management, or safety reporting. Once a pattern develops, the response may involve site-specific actions, cross-site trend assessment, statistical evaluation, protocol clarification, and revised monitoring priorities. A 2025 retrospective study of 14 clinical trials involving combination products found that longer study participation was associated with more protocol deviations and highlighted the importance of effective informed consent, experienced study staff, and risk-management strategies (Cilley et al., 2025). Although the sample was limited, the findings reinforce the operational value of preparedness and continuous control.
The cost of inefficient oversight should also be considered. Manasco and Bhatt (2022) argued that oversight approaches should be evaluated with evidence regarding their ability to identify high-risk errors, rather than assuming that extensive routine source data verification automatically provides greater quality. Spending heavily on low-value verification while meaningful systemic risks remain insufficiently examined is not a quality strategy; it is an inefficient allocation of resources.
Recent financial modeling provides a more concrete perspective. Dirks et al. (2026) analyzed actual RBQM use in 18 recently completed oncology trials together with published and proprietary benchmarks. Under the modeled 10% SDV scenario, RBQM was associated with monitoring-cost reductions of up to 18%, phase-duration reductions of 8% to 19%, and trial-level ROI multiples ranging from approximately 6 to 23. The analysis was oncology-specific and incorporated modeled assumptions, so its results should be interpreted within those boundaries. Nevertheless, it demonstrates that proactive, risk-focused oversight can create measurable value through earlier detection, targeted monitoring, and faster issue resolution.
The practical lesson is clear: the relevant comparison is not quality spending versus no quality spending. It is the planned cost of preventing and detecting meaningful risks early versus the uncontrolled cost of correcting them after they spread across sites, systems, and timelines.
Quality by Design Under ICH E6(R3)
Quality by Design begins by defining what must go right for a study to protect participants and produce reliable results. It does not attempt to eliminate every possible risk or apply the same controls to every process. Instead, it identifies critical-to-quality factors and aligns the protocol, operational plans, training, data flows, and oversight activities around those priorities.
ICH E8(R1), adopted by the FDA in 2022, describes QbD as a prospective approach to study quality. It calls for early identification of factors that are critical to participant protection, the reliability and interpretability of results, and the ability to reach meaningful conclusions. It also encourages open dialogue among stakeholders, attention to essential activities, and periodic review of critical-to-quality factors as the study evolves (FDA, 2022).
ICH E6(R3) translates this philosophy into a modern GCP framework. The guideline emphasizes proportionate approaches, operational feasibility, clear roles and responsibilities, fit-for-purpose systems, reliable records, and quality management focused on risks that matter (ICH, 2025). Importantly, sponsor responsibility does not disappear when activities are transferred to service providers. Agreements should define transferred activities, and sponsors should maintain appropriate oversight of those activities.
Applied in practice, QbD requires cross-functional decisions before first-patient-in. Teams should test whether eligibility criteria are operationally feasible, whether endpoints can be collected reliably, whether visit schedules are realistic for participants and sites, whether safety information can move through the required pathways on time, and whether critical data can be traced across systems. Each of these questions connects design choices with downstream quality and cost.
The approach also requires disciplined simplification. Every additional procedure, system, handoff, and documentation requirement can introduce burden and variability. A quality-focused team distinguishes activities that protect participants or support reliable conclusions from activities that add complexity without proportional value. This does not mean lowering standards. It means designing controls around the scientific and ethical purpose of the trial.
At ABRS, a QbD mindset informs feasibility review, functional planning, role assignment, site support, monitoring strategy, data review, issue escalation, and inspection readiness. The objective is to help sponsors identify operational weaknesses before they become recurring deviations or expensive remediation programs, while ensuring that final risk decisions remain visible to and controlled by the sponsor.
Quality by Design Under ICH E6(R3)
Quality by Design begins by defining what must go right for a study to protect participants and produce reliable results. It does not attempt to eliminate every possible risk or apply the same controls to every process. Instead, it identifies critical-to-quality factors and aligns the protocol, operational plans, training, data flows, and oversight activities around those priorities.
ICH E8(R1), adopted by the FDA in 2022, describes QbD as a prospective approach to study quality. It calls for early identification of factors that are critical to participant protection, the reliability and interpretability of results, and the ability to reach meaningful conclusions. It also encourages open dialogue among stakeholders, attention to essential activities, and periodic review of critical-to-quality factors as the study evolves (FDA, 2022).
ICH E6(R3) translates this philosophy into a modern GCP framework. The guideline emphasizes proportionate approaches, operational feasibility, clear roles and responsibilities, fit-for-purpose systems, reliable records, and quality management focused on risks that matter (ICH, 2025). Importantly, sponsor responsibility does not disappear when activities are transferred to service providers. Agreements should define transferred activities, and sponsors should maintain appropriate oversight of those activities.
Applied in practice, QbD requires cross-functional decisions before first-patient-in. Teams should test whether eligibility criteria are operationally feasible, whether endpoints can be collected reliably, whether visit schedules are realistic for participants and sites, whether safety information can move through the required pathways on time, and whether critical data can be traced across systems. Each of these questions connects design choices with downstream quality and cost.
The approach also requires disciplined simplification. Every additional procedure, system, handoff, and documentation requirement can introduce burden and variability. A quality-focused team distinguishes activities that protect participants or support reliable conclusions from activities that add complexity without proportional value. This does not mean lowering standards. It means designing controls around the scientific and ethical purpose of the trial.
At ABRS, a QbD mindset informs feasibility review, functional planning, role assignment, site support, monitoring strategy, data review, issue escalation, and inspection readiness. The objective is to help sponsors identify operational weaknesses before they become recurring deviations or expensive remediation programs, while ensuring that final risk decisions remain visible to and controlled by the sponsor.
Risk-Based Quality Management as a Continuous Operating Model
Quality by Design establishes priorities; RBQM converts those priorities into continuous operational control. A risk-based model defines critical data and processes, identifies how risks will be measured, assigns thresholds or triggers, specifies escalation pathways, and adapts oversight as information accumulates. This is fundamentally different from waiting for a monitoring visit, audit, or end-of-study reconciliation to reveal a pattern.
The FDA’s 2023 guidance on risk-based monitoring recommends that sponsors tailor monitoring approaches to the specific risks of a clinical investigation. Monitoring plans should explain what will be reviewed, how monitoring will be conducted, how important issues will be communicated, and how significant findings will be followed through to resolution (FDA, 2023). The guidance recognizes that centralized, remote, and on-site activities can be combined according to the risks and characteristics of the study.
Effective RBQM depends on leading indicators, not only lagging documentation. Examples include delayed data entry, aging queries, repeated protocol deviations, late safety follow-up, inconsistent informed-consent documentation, investigational product discrepancies, missing essential documents, unusual data distributions, high staff turnover, and delayed investigator review. No single metric proves that a site or study is failing. The value comes from evaluating patterns, context, criticality, and change over time.
A mature model also links detection with action. An alert without an owner, decision timeline, or documented outcome does not reduce risk. Teams need predefined routes for review and escalation, clear authority to intervene, and evidence that actions were proportionate and effective. This may involve focused site contact, targeted remote review, an on-site visit, revised training, process clarification, enhanced data surveillance, or formal CAPA.
The 2026 analysis by Dirks et al. suggests that this targeted approach can improve both efficiency and financial performance. The authors attributed much of the modeled value to time savings associated with more focused monitoring, earlier identification of operational and data-quality risks, and fewer delays in issue resolution, close-out, and completion. Their results support the idea that RBQM is not simply a reduction in SDV; it is a redistribution of oversight toward higher-value activities.
For sponsors, the governance requirement remains central. Risk-based execution should increase visibility, not reduce it. Dashboards, KRIs, QTLs, monitoring outputs, issue logs, vendor metrics, and escalation records should support transparent decisions and demonstrate why the chosen controls were appropriate. ABRS can contribute experienced functional resources and structured communication that help turn these data into timely action while maintaining sponsor oversight.
Building a Proactive and Inspection-Ready Quality Model
A proactive quality model must integrate people, processes, technology, and governance. Weakness in any one of these elements can undermine the others. A well-designed monitoring strategy will not compensate for unclear responsibilities. A validated system will not ensure reliable data if users are poorly trained. A complete procedure will not protect participants if teams do not recognize or escalate safety signals on time.
People are the first control. Roles should be assigned according to competence, study complexity, and regional requirements. Training should go beyond confirming that a document was read; it should establish whether individuals understand critical processes, decision boundaries, and escalation expectations. Ongoing oversight should also detect workload, turnover, or capability issues that may increase operational risk.
Processes provide consistency. Monitoring, data review, safety surveillance, TMF management, vendor oversight, deviation handling, CAPA, and change control should operate as connected components of one quality system. When these functions use different definitions, timelines, or escalation thresholds, issues can remain unresolved between teams. Integrated plans and governance forums help convert fragmented information into coordinated decisions.
Technology must be fit for purpose and controlled throughout its lifecycle. The EMA’s 2023 guideline requires attention to data integrity, ALCOA++ principles, system validation, access control, audit trails, security, backup, migration, archiving, and service-provider arrangements for computerized systems used in clinical trials (European Medicines Agency [EMA], 2023). The FDA’s 2024 guidance similarly recommends risk-based validation and emphasizes that sponsors remain responsible for the quality and integrity of data submitted in support of regulatory decisions (FDA, 2024).
Governance connects these controls and makes them inspection-ready. Decisions should be traceable: what signal was identified, who reviewed it, what risk was assessed, what action was selected, and whether that action was effective. Inspection readiness therefore is not a clean-up exercise performed shortly before an authority visit. It is the natural result of contemporaneous, reliable, and accessible evidence produced throughout study conduct.
ABRS supports this model through functional expertise that can be aligned to the sponsor’s procedures, systems, and governance structure. Depending on the program, support may include monitoring, clinical operations, data review, quality and audit activities, regional execution, vendor coordination, issue management, and inspection-readiness preparation. The purpose is not to replace sponsor accountability, but to strengthen execution, provide operational visibility, and help ensure that emerging risks are addressed before they become systemic failures.
The most effective model is therefore both preventive and adaptive. It prevents avoidable problems through thoughtful design and clear controls, detects meaningful changes through risk-based oversight, and adapts resources as the study’s risk profile evolves. That combination protects participants, preserves data integrity, and keeps clinical development moving forward.
Conclusion
Compliance is often described as expensive because its visible costs appear early: qualified personnel, training, system validation, monitoring, governance, audits, and documentation. The costs of weak quality are less visible at first, but they can be substantially more disruptive. They emerge through delayed enrollment, repeated monitoring, protocol deviations, data-cleaning backlogs, safety-reporting deficiencies, incomplete TMFs, CAPAs, retraining, inspection risk, and lost development time.
Current regulatory guidance does not support a model based on maximum checking. It supports a model based on thoughtful design, proportionate controls, reliable information, clear responsibility, and continuous oversight. ICH E8(R1), ICH E6(R3), FDA risk-based monitoring guidance, and EMA and FDA expectations for electronic systems all point toward the same principle: quality should be embedded into how the trial is designed and operated, not added after problems occur.
Evidence is also beginning to quantify the operational and financial return of this approach. The 2026 RBQM study by Dirks and colleagues provides a compelling, although context-specific, indication that focused oversight can reduce monitoring costs and development time. Together with research questioning the effectiveness of routine, undifferentiated SDV, it strengthens the case for directing resources toward critical risks and measurable oversight outcomes.
At ABRS, we believe the smartest investment is not fixing quality after it fails. It is building quality from day one through experienced professionals, risk-based execution, transparent governance, and sponsor-controlled decision-making. Organizations that adopt this approach are better positioned to protect participants, preserve data integrity, maintain inspection readiness, and advance clinical programs with greater confidence.
References
Cilley, K. N., Kaliaev, A. O., & Malikova, M. A. (2025). Impact of protocol amendments, personnel experience and social determinants of health on study protocol adherence in clinical trials with combination products. Therapeutic Innovation & Regulatory Science, 59(6), 1506-1515. https://doi.org/10.1007/s43441-025-00859-y
Dirks, A., de Viron, S., McFarlane, K., & Getz, K. A. (2026). Quantifying the financial return on investment of risk-based quality management implementation in clinical development. Therapeutic Innovation & Regulatory Science. Advance online publication. https://doi.org/10.1007/s43441-026-01002-1
European Medicines Agency. (2023, March 9). Guideline on computerised systems and electronic data in clinical trials. https://www.ema.europa.eu/system/files/documents/regulatory-procedural-guideline/guideline_on_computerised_systems_and_electronic_data_in_clinical_trials_en.pdf
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2025). ICH harmonised guideline: Guideline for Good Clinical Practice E6(R3). https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106_ErrorCorrections_2025_1024.pdf
Manasco, P., & Bhatt, D. L. (2022). Evaluating the evaluators: Developing evidence of quality oversight effectiveness for clinical trial monitoring: Source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high-risk errors. Contemporary Clinical Trials, 117, 106764. https://doi.org/10.1016/j.cct.2022.106764
U.S. Food and Drug Administration. (2022, April). E8(R1) general considerations for clinical studies: Guidance for industry. https://www.fda.gov/media/157560/download
U.S. Food and Drug Administration. (2023, April). A risk-based approach to monitoring of clinical investigations: Questions and answers: Guidance for industry. https://www.fda.gov/media/121479/download
U.S. Food and Drug Administration. (2024, October). Electronic systems, electronic records, and electronic signatures in clinical investigations: Questions and answers: Guidance for industry. https://www.fda.gov/media/166215/download
